Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Saved in:
| Title: | Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK. |
|---|---|
| Authors: | Wei J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Matthews PC; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; The Francis Crick Institute, 1 Midland Road, London, UK.; Division of infection and immunity, University College London, London, UK., Stoesser N; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.; The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Newton JN; European Centre for Environment and Human Health, University of Exeter, Truro, UK., Diamond I; Office for National Statistics, Newport, UK., Studley R; Office for National Statistics, Newport, UK., Taylor N; Office for National Statistics, Newport, UK., Bell JI; Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK., Farrar J; Wellcome Trust, London, UK., Kolenchery J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK., Marsden BD; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Hoosdally S; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Jones EY; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Stuart DI; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Crook DW; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.; The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Peto TEA; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.; The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Walker AS; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.; MRC Clinical Trials Unit at UCL, UCL, London, UK., Pouwels KB; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Eyre DW; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. david.eyre@bdi.ox.ac.uk.; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. david.eyre@bdi.ox.ac.uk.; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK. david.eyre@bdi.ox.ac.uk.; The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. david.eyre@bdi.ox.ac.uk. |
| Corporate Authors: | COVID-19 Infection Survey team |
| Source: | Nature communications [Nat Commun] 2023 May 16; Vol. 14 (1), pp. 2799. Date of Electronic Publication: 2023 May 16. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-38275-1 |
